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This series of studies was designed to assess in nor­
mal volunteers the relationships between various 
doses (5, 10, 20, 40, 80, and 120 mg) of the orally ac­
tive angiotensin II antagonist losartan (DuP 753, 
MK-954) and their inhibitory effect on the pressure 
response to a given bolus of angiotensin I or II. It 
was found that the maximal inhibitory effect was 
reached with a dose of 80 mg. The minimal dose 
necessary for maximal efficacy would therefore be 
expected to be between 40 and 80 mg. The effect 
lasted for more than 24 h and was related almost 
exclusively to the circulating levels of the active 
metabolite EXP3174. It remains to be demonstrated 
in hypertensive patients that the same dose rela­
tionship holds for the antihypertensive effect, but 
preliminary data already suggest that this is the 
case. Am J Hypertens 1992;5:243S-246S 
K E Y W O R D S : Angiotensin I I receptor antagonists, 
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Interruption of the renin-angiotensin system (RAS) as a means of controlling hypertension has received a great deal of attention in recent years. The most useful therapeutic agents to evolve from these in­
vestigations are the angiotensin converting enzyme 
(ACE) inhibitors. Captopril1 and enalapril,2 which were 
initially introduced for treating severe or renin-depen-
dent hypertension, have been shown to be effective in 
managing milder forms of essential hypertension in 
which there is no clear activation of the renin-angioten­
sin system. This suggests that the renin-angiotensin 
system plays a broader role in the pathophysiology of 
hypertension. 3 
While ACE inhibition is effective in controlling blood 
pressure, this does not occur without some side effects 
such as cough and angioedema. These side effects are 
believed to be related to the fact that ACE, which is a 
relatively nonspecific peptidyl dipeptidase, is involved 
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in the breakdown of bradykinin. Inhibition of ACE thus 
leads to potentiation of bradykinin actions, which may 
be responsible for the side effects. 
Recently, specific, orally active, nonpeptide angio­
tensin II (ANG II) receptor antagonists have been devel­
oped. 4 Losartan is the first of these agents to enter clini­
cal trials. The potential advantages of this approach to 
blocking the renin-angiotensin system are that, by inhib­
iting the hormone from binding to its receptor, the sys­
tem can be specifically turned off regardless of the 
source of ANG II. In addition, since ACE is not affected, 
there is no potentiation of bradykinin and, therefore, no 
cough or angioedema would be expected during ther­
apy with losartan. 
METHODS 
The initial studies in human subjects assessed the toler­
ance and inhibitory effect of losartan (DuP 753) on the 
pressor action of exogenous ANG I or ANG II. In the 
first study, single oral doses of losartan (2.5, 5, 10, 20, 
and 40 mg) were studied ν placebo. 5 A dose-response 
relationship was established with regard to systolic 
blood pressure responses to increasing intravenous 
doses of ANG (I or II) in each subject. The test dose of 
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ANG I selected was one that increased systolic blood 
pressure by about 30 mm Hg. This dose was then used to 
define the baseline systolic blood pressure response to 
ANG and became the challenge dose for that subject. 
The effect of losartan was established by bolus injec­
tions of the challenge dose of ANG given from 15 min to 
27 h after ingestion of losartan (dissolved in 20 mL of tap 
water). 
RESULTS 
Losartan had no effect on resting blood pressure or heart 
rate and was well-tolerated in this study. Doses of 2.5 
and 5 mg of losartan had no effect on systolic blood 
pressure response to ANG I when compared with pla­
cebo. Doses of 10, 20, and 40 mg of losartan produced a 
dose-related inhibition of the systolic blood pressure 
response to ANG I (Figure 1), which was accompanied 
by increases in plasma ANG II. Plasma aldosterone 
levels fell after the administration of losartan, but these 
changes were not different from placebo (Figure 2). 
From Figure 1 it is evident that the duration of the 
ANG I-blocking effect of losartan is prolonged, up to 24 
h or more at the 40 mg dose. Figure 3 compares the time 
course of the mean plasma levels of losartan with the 
levels of immunoreactive ANG II and with the inhibi­
tion of the systolic blood pressure response to ANG I 
after single oral doses of 20 and 40 mg losartan. It is clear 
that the effects on systolic blood pressure and immuno­
reactive ANG II persist long after plasma levels of losar­
tan have disappeared. The prolonged effects of the drug 
are due to the presence of the active metabolite E-3174, 
which has a half-life of approximately 6.5 h. 
The second study of losartan in human subjects was a 
multiple-dose tolerance study, which also assessed the 
inhibitory effects of repeated dosing with losartan on 
the response of systolic blood pressure to ANG II. 6 The 
doses of losartan studied were 5 , 1 0 , 2 0 , or 40 mg, given 
orally once a day for 8 days. These doses were compared 
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FIGURE 1. Plots of effects of single doses of oral DuP 753 (10, 
20, or 40 mg) or placebo on systolic blood pressure (SBP) response 
(mean) to test doses of angiotensin I (ANG I) in healthy volunteers. 
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FIGURE 2. Effects of single doses of oral DuP 753 (10, 20, or 40 
mg) or placebo on plasma aldosterone (lower panel) and immuno­
reactive angiotensin II (ANG II) (upper panel). Bullets on ab­
scissa, ANG I test-dose injections. Values are given as mean ± 
SEM. 
with placebo given for 8 days. This study was carried out 
in a similar fashion to the single-dose study, in that 
dose-response relationships were established with re­
gard to the systolic blood pressure response to exoge­
nous ANG II. The challenge dose was again targeted to 
cause an approximately 30 mm Hg increase in systolic 
blood pressure. The ANG II challenge was carried out 
on days 2, 4, and 8 before and 6 and 12 h following 
ingestion of losartan or placebo. Additional challenges 
were performed 24 h before adminstration of the drug 
on day 1, and at 24, 30, and 36 h after the last dose on 
day 8. 
Losartan was well-tolerated in this study, with no 
clinically significant side effects observed after multiple 
dosing. As in the first study, losartan had no effect on 
resting blood pressure or heart rate. 
Losartan (10 to 40 mg) caused a dose-dependent de­
crease in the systolic blood pressure response to ANG II 
throughout the treatment period, when compared with 
placebo. The degree of blockade achieved with the 20 
and 40 mg doses was similar 6 h after drug intake on 
AJH-DECEMBER 1992-VOL 5, NO. 12, PART 2 CLINICAL EXPERIENCE WITH All RECEPTOR ANTAGONISTS 245S 
FIGURE 3. Comparisons of DuP 753 plasma levels (mean) with 
inhibition of systolic blood pressure (BP) response to test doses 
of angiotensin I (ANG I) (upper panel) and immunoreactive 
ANG II (lower panel) after single oral doses of DuP 753 (20 and 
40 mg). 
days 1, 4, and 8 (P < .01) compared with placebo. On 
days 4 and 8, subjects receiving 40 mg losartan showed a 
clear trend toward a reduced response to ANG II imme-
diately before the morning dose of the drug (Figure 4). 
At peak effect, the 40 mg doses of losartan caused an 
approximately 7 0 % reduction in the systolic blood pres-
sure response to ANG II. 
Plasma renin activity and ANG II levels also re-
sponded with a dose-dependent compensatory rise 
which was more pronounced on day 8 than on day 1 of 
drug administration (Figure 5). The long duration of the 
blocking effect of losartan is reflected in the plasma 
renin activity and ANG II levels on day 8; these levels 
were clearly increased prior to the administration of the 
20 and 40 mg dose. This prolonged duration of action is 
undoubtedly due to the presence of the active metabo-
lite of losartan (E-3174). 
Subsequently, the effects of 40, 80, and 120 mg oral 
doses of losartan on systolic blood pressure responses to 
ANG II were studied in the same fashion. The 80 mg 
dose produced a maximal blockade of the systolic blood 
pressure response to ANG II ( > 8 0 % ) . 6 In this study, 
Munafo and coworkers investigated the relationships 
between plasma concentrations of losartan; its active 
metabolite, E-3174; and ANG II blockade in six healthy 
subjects who received 40, 80, or 120 mg of losartan or 
placebo at 1 week intervals in a cross-over protocol. 
E-3174 reached higher plasma concentrations and was 
eliminated more slowly than losartan; E-3174 plasma 
levels paralleled the profile of ANG II blockade more 
closely than did plasma levels of losartan. The inhibition 
of the blood pressure response was dose-dependent. 
The concentration-response curve suggested that 
E-3174 levels higher than about 200 ng/mL do not fur-
ther enhance the effect. There was no gain in either the 
degree or the duration of inhibition from increasing the 
oral dose of losartan beyond 80 mg. 
The reactive increase in plasma renin activity and cir-
culating ANG II in these normotensive subjects was 
highly variable and could not be used to predict the 
inhibition in individual subjects. The researchers con-
cluded that the effect of losartan is most likely attributa-
ble to the long-acting metabolite E-3174. 
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FIGURE 4. Plots of effects of 8 consecutive days of treatment 
with two oral doses of either DuP 753 (20 or 40 mg) or placebo on 
systolic blood pressure (SBP) response (mean) to test doses of an-
giotensin II (ANG II) in healthy volunteers. 
DISCUSSION 
The results of these studies led to the expectation that 
the effective antihypertensive dose of losartan would be 
between 40 and 80 mg and would have a duration of 
effect that would support a once-daily dose regimen. 
Nelson and coworkers 7 have reported the antihyperten-
sive effects of losartan (50, 100, or 150 mg taken orally 
once daily) compared with placebo and 10 mg enalapril 
taken orally once daily in 98 mildly to moderately hy-
pertensive patients. After 5 days of dosing, a significant 
decrease in both systolic and diastolic blood pressure 
was seen when compared with placebo. There was no 
difference in the magnitude of response between the 
three doses of losartan or the 10 mg dose of enalapril. It 
would appear that the losartan doses studied are at the 
high end of the dose-response curve, since 100 and 150 
mg doses had no additional effect on blood pressure. 
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Day 1 
FIGURE 5. Effects of four different daily oral doses of 
DuP 753 (5, 10, 20, or 40 mg) or placebo (n = 6 for each 
dose except dose of 20 mg, where η = 5) on plasma renin 
activity and immunoreactive angiotensin II (ANG II), 
measured before and 6 h after drug intake on days 1 and 8. 
Values are given as mean ± standard enor of the mean. 
*P < .05. **P < .01 ν placebo. 
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Further studies are in progress to define the dose-re­
sponse relationships of losartan with regard to blood-
pressure lowering. 
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